Plocamium Global Insights
Gilead Sciences secured a rare commercial advantage on May 22, 2026, when the FDA approved Hepcludex (bulevirtide-gmod) as the first treatment for chronic hepatitis delta virus infection in adults—ending a decades-long therapeutic drought for a disease that accelerates liver failure faster than hepa
429 Folgen
Kommentare
0Sei die erste Person, die kommentiert
Melde dich jetzt an und werde Teil der Plocamium Global Insights-Community!